Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for X4 Pharmaceuticals, Inc. (XFOR : NSDQ)
 
 • Company Description   
X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.

Number of Employees: 143

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.89 Daily Weekly Monthly
20 Day Moving Average: 469,504 shares
Shares Outstanding: 5.79 (millions)
Market Capitalization: $10.94 (millions)
Beta: 0.54
52 Week High: $26.96
52 Week Low: $1.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -48.92% -51.69%
12 Week -70.26% -75.05%
Year To Date -91.42% -91.96%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
61 North Beacon Street 4th Floor
-
Boston,MA 02134
USA
ph: 857-529-8300
fax: -
daniel@lifesciadvisors.com http://www.x4pharma.com
 
 • General Corporate Information   
Officers
Paula Ragan - President and Chief Executive Officer
Michael S. Wyzga - Chairman
Adam S. Mostafa - Chief Financial Officer and Treasurer
William E. Aliski - Director
Gary J. Bridger - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98420X202
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 5.79
Most Recent Split Date: 4.00 (0.03:1)
Beta: 0.54
Market Capitalization: $10.94 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-3.62 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-9.54 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.48
Price/Cash Flow: -
Price / Sales: 0.35
EPS Growth
vs. Year Ago Period: 100.51%
vs. Previous Quarter: 100.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 1,908.86%
ROE
06/30/25 - -
03/31/25 - -181.56
12/31/24 - -321.45
ROA
06/30/25 - -
03/31/25 - -54.36
12/31/24 - -88.01
Current Ratio
06/30/25 - -
03/31/25 - 3.70
12/31/24 - 3.41
Quick Ratio
06/30/25 - -
03/31/25 - 3.58
12/31/24 - 3.33
Operating Margin
06/30/25 - -
03/31/25 - -288.23
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - 46.54
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - 47.58
12/31/24 - -1,452.48
Book Value
06/30/25 - -
03/31/25 - 3.96
12/31/24 - 3.90
Inventory Turnover
06/30/25 - -
03/31/25 - 2.40
12/31/24 - 0.52
Debt-to-Equity
06/30/25 - -
03/31/25 - 3.30
12/31/24 - 3.41
Debt-to-Capital
06/30/25 - -
03/31/25 - 76.72
12/31/24 - 77.30
 

Powered by Zacks Investment Research ©